Guardian Pharmacy Services, Inc. (GRDN) Research

Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.

Market snapshot

Symbol
GRDN
Price
$42.41
Day change
-2.28%
Market cap
$2.7B
P/E ratio
50.61x
52-week range
19.295-44
Sector
Healthcare
Industry
Medical - Distribution
Next earnings
in 2 months
Analyst price target
$41.00

Peer companies

  • Edgewise Therapeutics, Inc. (EWTX)
  • Janux Therapeutics, Inc. (JANX)
  • Pediatrix Medical Group, Inc. (MD)
  • Mesoblast Limited (MESO)
  • National HealthCare Corporation (NHC)
  • Nuvation Bio Inc. (NUVB)
  • PROCEPT BioRobotics Corporation (PRCT)
  • QuidelOrtho Corporation (QDEL)

Recent insider activity

  • COSLER STEVEN D — A-Award (4028 shares) on 2026-05-05
  • LEWIS RANDALL J — A-Award (4028 shares) on 2026-05-05
  • Patchett Mary Sue — A-Award (4028 shares) on 2026-05-05
  • Eakins Richard — trade (0 shares) on 2026-04-01
  • Eakins Richard — trade (36052 shares) on 2026-04-01

Open Guardian Pharmacy Services, Inc. (GRDN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.